Hyderabad, June 13 -- Dr Reddy's Laboratories Ltd on Saturday announced the launch of Bosutinib Tablets 400 mg, a generic equivalent of Bosulif, in the United States, marking its entry as the first generic player in the market for the strength and further expanding its oncology portfolio.
The Hyderabad-based pharmaceutical major said it has partnered with MSN Laboratories Pvt Ltd. for the product. Under the collaboration, Dr Reddy's holds exclusive marketing rights in the United States, while MSN is responsible for product development and manufacturing.
Bosutinib Tablets 400 mg was a first-to-file product and is eligible for 180 days of generic drug exclusivity in the US market, the company said in a statement.
Commenting on the launch, ...